December 10, 2024
GSK and Relation Therapeutics Collaborate on Fibrosis and Osteoarthritis Research with AI-Driven Approach
Relation Therapeutics, GSK, Fibrosis, Osteoarthritis, AI in drug discovery, Machine learning in biotech
2024 Biotech IPOs: Insights and Trends
Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.
Eli Lilly Announces $15 Billion Share Buyback Plan and 15% Dividend Increase
Eli Lilly, Share Buyback, Dividend Increase, Pharmaceutical Industry, Stock Market
Biotech Funding Boom: Tasca and Citryll Secure Significant Investments
Biotech fundraising, venture capital, Tasca, Citryll, Fierce Biotech Fundraising Tracker ’24
Belharra Biotech Cuts 21 Jobs Amid Industry-Wide Restructuring
Belharra Biotech, layoffs, chemoproteomics, biotech industry, restructuring
Relmada Therapeutics Explores Strategic Alternatives Following Discontinuation of Two Phase 3 Trials
Relmada Therapeutics, Phase 3 trials, Strategic alternatives, REL-1017, REL-P11, Central nervous system diseases, Metabolic disorders
Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies
BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety
Belharra Therapeutics Reduces Workforce by 40%, Laying Off 21 Employees
Belharra Therapeutics, layoffs, workforce reduction, biotech industry, drug discovery
European Commission Approves Novo Holdings’ $16.5B Acquisition of Catalent
Novo Holdings, Catalent, European Commission, Acquisition, Pharmaceutical Industry
Dutch Biotech Citryll Secures €85M Funding from J&J and Novartis for Inflammatory Disease Therapy
Citryll, Inflammatory disease therapy, Neutrophil Extracellular Traps (NETs), Series B funding, Johnson & Johnson Innovation, Novartis Venture Fund, Forbion